Opioid Receptors Influence Ischemia-Reperfusion Injury

This study has suspended participant recruitment.
Information provided by:
Radboud University
ClinicalTrials.gov Identifier:
First received: September 12, 2005
Last updated: March 27, 2008
Last verified: March 2008

The most powerful protective mechanism against ischemia-reperfusion injury other than rapid reperfusion is ischemic preconditioning. Ischemic preconditioning is defined as the development of tolerance to ischemia-reperfusion injury by a previous short bout of ischemia resulting in a marked reduction in infarct size. This mechanism can be mimicked by several pharmacological substances such as adenosine and morphine.

We, the researchers at Radboud University Nijmegen Medical Centre, have recently developed a method in which we can detect ischemia-reperfusion injury in the human forearm by using Annexin A5 scintigraphy (Rongen et al). With this method we will determine whether opioid receptors are involved in ischemic preconditioning. We expect to find that morphine can mimic ischemic preconditioning and that acute ischemic preconditioning can be blocked with the opioid receptor antagonist naloxon. This study will increase our knowledge about the mechanism of ischemic preconditioning and may also provide leads to exploit this endogenous protective mechanism in a clinical setting.

Condition Intervention
Ischemia-Reperfusion Injury
Drug: morphine
Drug: naloxone
Drug: Technetium-TC99m-labeled Annexin A5
Procedure: forearm ischemic exercise
Procedure: ten minute forearm ischemia

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Double-Blind
Official Title: Opioid Induced Acute Preconditioning

Further study details as provided by Radboud University:

Primary Outcome Measures:
  • Percentual difference in Annexin A5 targetting between the experimental and control arm 1 and 4 hours after intravenous injection

Estimated Enrollment: 40
Study Start Date: January 2005

Ages Eligible for Study:   18 Years to 50 Years
Genders Eligible for Study:   Male
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • Healthy male volunteers

Exclusion Criteria:

  • Exposition to radiation due to imaging techniques in the previous five years
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00184938

Radboud University Nijmegen Medical Centre / Department of Pharmacology and Toxicology
Nijmegen, Gelderland, Netherlands, 6500 HB
Sponsors and Collaborators
Radboud University
Principal Investigator: Gerard Rongen, MD, Phd Radboud University Nijmegen Medical Centre / Department of Pharmacology and Toxicology
  More Information

ClinicalTrials.gov Identifier: NCT00184938     History of Changes
Other Study ID Numbers: OPIRI 
Study First Received: September 12, 2005
Last Updated: March 27, 2008
Health Authority: Netherlands: The Central Committee on Research Involving Human Subjects (CCMO)

Keywords provided by Radboud University:
ischemic preconditioning

Additional relevant MeSH terms:
Reperfusion Injury
Cardiovascular Diseases
Pathologic Processes
Postoperative Complications
Vascular Diseases

ClinicalTrials.gov processed this record on May 26, 2016